A Korean company developing cell-based cancer therapeutic vaccines using autologous B cells and monocytes is looking for partners under commercial agreement with technical assistance, investment agreement and research & development cooperation agreement.

Short summary A Korean SME is developing cell-based cancer therapeutic vaccines using autologous B cells and monocytes. This new platform technology is highly cost-effective and required only one day to be manufactured vaccine targeting various cancer treatment by changing antigens. The company is looking for partners under commercial agreement with technical assistance, investment agreement and research & development cooperation agreement.

Full description Established in 2006, the Korean company has been developing cell-based cancer therapeutic vaccines using authentic adenoviral vector technology. Main elements and mechanisms of the vaccine are as follows. 1. Main elements a. Autologous B cells and monocytes - Serve as antigen-presenting cells which can stimulate T cell immune responses b. Tumor antigen gene or Neo-epitope peptides - Tumor-specific and over expressed antigen in cancer cells - Being transferred into B cells and monocytes - Enable efficient gene delivery by proprietary adenoviral vector c. Adjuvant, α-galactosyl ceramide - Well known NKT cell ligand - Stimulate immune response via NKT cell activation 2. Mechanisms a. Induce innate immunity (NK, NKT cells) and adaptive immunity (T cells, Ab) b. Reinvigorate exhausted immune effectors Based on adenoviral vector technology, the company can develop products targeting various cancer treatments by changing antigens. So far, 5 pipelines of cell-based cancer therapeutic vaccines are under development, one of which is under joint research with major pharmaceutical company for cancer treatment, and another has signed license agreement to major Korean bio company. The development stages of the 5 pipelines are as follows. - Vaccine-C (cervical cancer): Phase IIa for monotherapy (completed), Phase IIa for combination (on-going) - Vaccine -B (GI & other cancer): Phase I (completed) - Vaccine -P (prostate cancer): Phase I (IND approval) - Vaccine -M (melanoma): Phase I (IND submission) - Vaccine -Neo (personalized): preclinical The company is looking for partners under commercial agreement with technical assistance, investment agreement and research & development cooperation agreement.

Advantages and innovations 1. Induce broad spectrum of immune responses compared to competitors - Inhibition of recurrence by memory immune response - Overcoming cancer immune evasion of T cells by NK/NKT cell response and reinvigorating exhausted immune effectors 2. Fast production and cost-effectiveness - Fast and cost-effective manufacturing process via use of B cells and monocytes - Can be manufactured with one day only 3. Scalability - Efficient pipeline expansion by switching tumor antigens - Patent evergreening via the introduction of novel fusion antigens

Contact / source: NEXT EEN Widgets (europa.eu)